Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS EBITDA Margin
EBITDA as a percentage of revenue.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 14.8%
EBITDA Margin was 14.8% in Q1 FY2026, up 12.8 pp from a year earlier. On a trailing-twelve-month basis it was 14.7%, up 16.6 pp year over year. Over 3 fiscal years it widened by 67.2 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 10.0% for the fiscal year ending Dec 2026, up from 4.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 14.8%-1.6 pp QoQ
- Last fiscal yearDec 2025
- 4.4%+11.2 pp YoY
- LTMMar 2026
- 14.7%+16.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.8 pp | +2.5 pp | -10.3 pp |
| 1 year | +11.2 pp | +5.7 pp | -5.6 pp |
| 3 years | +67.2 pp | +29.2 pp | -38.0 pp |
| 5 years | +30.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 4.4%
- Year-over-year change
- +11.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.4% | +11.2pp |
| FY2024 | 2024-12-31 | -6.9% | +7.6pp |
| FY2023 | 2023-12-31 | -14.5% | +48.4pp |
| FY2022 | 2022-12-31 | -62.9% | +166.3pp |
| FY2021 | 2021-12-31 | -229.2% | — |
EBITDA Margin vs competitors
How XERS compares with its peers on the latest reported figures
- XERS's LTM Mar 2026 EBITDA Margin of 14.7% is the 2nd highest of the 6 companies compared; the peer median is 6.3%.
- Its year-over-year change of +16.6 pp is the 3rd highest of 6, against a peer median of +9.1 pp.
- Over three fiscal years its change of +67.2 pp compares with a peer median of +51.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 21.5% | +42.1 pp | +1018.2 pp | |
| LTM Mar 2026 | 14.7% | +16.6 pp | +67.2 pp | |
| LTM Mar 2026 | 7.6% | -20.1 pp | +64.3 pp | |
| LTM Mar 2026 | 6.3% | +9.1 pp | +39.4 pp | |
| LTM Jun 2026 | 3.5% | -14.4 pp | -20.8 pp | |
SEPNSepterna, Inc. | LTM Sep 2026 | -59.3% | +282.9 pp | — |
MBXMBX Biosciences, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding XERS) | 6.3% | +9.1 pp | +51.9 pp | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.59M | 110.25M | 163.91M | 203.07M | 291.85M |
| Cost of Revenue | 13.32M | 22.63M | 28.65M | 36.83M | 53.41M |
| Gross Profit | 36.27M | 87.61M | 135.27M | 166.24M | 238.43M |
| Gross Margin | 73.1% | 79.5% | 82.5% | 81.9% | 81.7% |
| Research & Development | 25.16M | 20.97M | 22.34M | 25.56M | 31.17M |
| Selling, General & Admin | 125.72M | 137.75M | 146.1M | 163.48M | 182.37M |
| Operating Expenses | 151.43M | 169.55M | 179.28M | 199.88M | 213.54M |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| EBITDA | (113.67M) | (69.31M) | (23.74M) | (13.99M) | 12.71M |
| EBITDA Margin | -229.2% | -62.9% | -14.5% | -6.9% | 4.4% |
| Operating Income | (115.16M) | (81.94M) | (44.01M) | (33.65M) | 24.9M |
| Operating Margin | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% |
| Interest Income | 313K | 2.58M | 4.75M | 5.32M | 4.74M |
| Interest Expense | 7.18M | 14.1M | 26.61M | 33.18M | 29.08M |
| Other Income / Expenses | (7.57M) | (14.14M) | (19.49M) | (23.46M) | (24.34M) |
| Income Before Tax | (122.73M) | (96.08M) | (63.5M) | (57.1M) | 554K |
| Pre-Tax Margin | -247.5% | -87.2% | -38.7% | -28.1% | 0.2% |
| Income Tax Expense | 0 | (1.42M) | (1.25M) | (2.27M) | 0 |
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Net Margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
| EPS (Basic) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| EPS (Diluted) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| Weighted Avg Shares | 79.03M | 135.63M | 137.67M | 146.77M | 160.43M |
| Weighted Avg Shares (Diluted) | 79.03M | 135.63M | 137.67M | 146.77M | 172.74M |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.